European Pharmaceutical Review

JANUARY 23, 2025

For instance, patent expiries are set to wipe out $300 billion in revenues by 2028. 4 Looking ahead, China is becoming an increasingly important research and development (R&D) target for companies seeking to license-in antibody-drug conjugates (ADCs) and other novel oncology treatments. EY (Ernst & Young). cited 2025Jan].

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Medico Reach

OCTOBER 17, 2022

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Medico Reach

OCTOBER 17, 2022

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

European Pharmaceutical Review

FEBRUARY 14, 2023

A key benefit of mRNA therapeutics is that manufacturing time is fast compared to antibodies or protein-based drugs. Robust analytical methods are needed to establish safety, potency, and purity of mRNA therapeutics in large-scale manufacturing. billion during 2028, GlobalData forecasted in its report.

Food and Drug Administration 105

Food and Drug Administration Medicine Safety Manufacturing 105